News Sentiment

ARTL sentiment intelligence

Artelo Biosciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.15 Week of 17 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+6.5% over one week, -8.7% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Artelo Biosciences (ARTL) awards stock options to director Douglas Blayney

Market Reaction

Price moving ahead of tone

68/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction 6.5% Price confirming higher
Trend fit Trend inactive -8.7% over four weeks
Fair value -93.9% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 20
Neutral 36
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 20
Market source 9
Quiver Quantitative 4
TradingView 3
Investing.com 3
The Manila Times 3
GlobeNewswire 3
Quartr 2

Event Lens

What the news is about

Classified themes
Market update 36
Earnings 20
Regulatory and legal 2
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 59
Quartr Direct company coverage

Artelo Biosciences (ARTL) Proxy filing Summary

Artelo Biosciences' annual meeting on July 17, 2026, will address three key proposals: electing Class III directors, increasing authorized common stock from 166,666,667 to 500,000,000 shares, and approving the issuance of more than 20% of outstanding common stock for Nasdaq compl

Tone
Neutral 50/100
Event
Market update
Published
19 Jul 2026 03:10
Source
Quartr
Quartr Direct company coverage

Artelo Biosciences (ARTL) AGM 2026 Summary

Artelo Biosciences (ARTL) held its 2026 Annual General Meeting, where shareholders considered several key proposals. These included the re-election of three Class III directors, an amendment to increase the authorized common stock from 166,666,667 to 500 million, and approval for

Tone
Neutral 50/100
Event
Regulatory and legal
Published
17 Jul 2026 20:11
Source
Quartr
Stock Titan Direct company coverage

Artelo Biosciences (NASDAQ: ARTL) details 2026 director and shareholder vote tallies

Artelo Biosciences, Inc. (NASDAQ: ARTL) reported the results of its Annual Meeting of Stockholders held on July 17, 2026. Stockholders voted on the re-election of three Class III directors and approved two other proposals, including an increase in authorized common stock and a sh

Tone
Neutral 50/100
Event
Earnings
Published
17 Jul 2026 20:11
Source
Stock Titan
TradingView Direct company coverage

ARTL: All proposals, including director elections and share increases, were approved

Artelo Biosciences, Inc. (ARTL) shareholders approved all proposals during their 2026 AGM, including director elections, an increase in authorized shares, and a major equity issuance. No shareholder questions were raised during the Q&A session. This information is based on the co

Tone
Positive 74/100
Event
Market update
Published
17 Jul 2026 16:11
Source
TradingView
Investing.com Direct company coverage

Artelo presents preclinical data on osteoarthritis pain drug

Artelo Biosciences announced preclinical study results for ART26.12, its osteoarthritis pain drug, showing it reduced pain behaviors in studies and had comparable efficacy to naproxen with fewer side effects. The company plans to start a clinical study in Q4 to evaluate its safet

Tone
Positive 71/100
Event
Earnings
Published
17 Jul 2026 10:11
Source
Investing.com
www.marketscreener.com Direct company coverage

Artelo Biosciences, Inc. Announces Results from Nonclinical Osteoarthritis Study Supporting ART26.12 as Potential First-In-Class New Therapy for Chronic Pain Conditions

Artelo Biosciences announced positive nonclinical study results for ART26.12, its FABP5 inhibitor, showing its potential as a first-in-class treatment for osteoarthritis pain. The drug demonstrated efficacy comparable to naproxen in reducing pain, while significantly minimizing g

Tone
Positive 90/100
Event
Earnings
Published
16 Jul 2026 18:09
Source
www.marketscreener.com
Market source Direct company coverage

Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions

Artelo Biosciences announced positive results from a nonclinical osteoarthritis study for its proprietary compound ART26.12, a selective FABP5 inhibitor. The study showed ART26.12 significantly reduced OA-associated pain behaviors comparable to naproxen, but with significantly le

Tone
Positive 73/100
Event
Earnings
Published
16 Jul 2026 14:40
Source
Market source
The Manila Times Direct company coverage

Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026

Artelo Biosciences is reminding its shareholders to vote their shares before its Annual Meeting on July 17, 2026. The company emphasizes that submitting a proxy is crucial for establishing the necessary quorum, regardless of how shareholders choose to vote. This participation ens

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 02:09
Source
The Manila Times
Stock Titan Direct company coverage

Every Artelo proxy helps reach quorum for July 17 meeting

Artelo Biosciences is reminding shareholders to vote their shares in advance of its virtual Annual Meeting on July 17, 2026, to ensure a quorum is met. The company emphasizes that every proxy submitted, regardless of the vote (FOR, AGAINST, or ABSTAIN), contributes to establishin

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 12:46
Source
Stock Titan
grafa.com Direct company coverage

Artelo reports ART27.13 pain study results

Artelo Biosciences announced nonclinical results showing its drug candidate ART27.13 reduced neuropathic pain behaviors in an animal model. The cannabinoid receptor agonist decreased mechanical allodynia and thermal hyperalgesia after repeated dosing. These findings support furth

Tone
Positive 76/100
Event
Earnings
Published
13 Jul 2026 18:10
Source
grafa.com
Investing.com Direct company coverage

Artelo reports positive neuropathic pain study results for ART27.13

Artelo Biosciences announced positive nonclinical study results for its drug candidate ART27.13, showing it reduced neuropathic pain in a paclitaxel-induced peripheral neuropathy model. The company, facing financial challenges with a 98% stock drop over the past year, is also adv

Tone
Positive 63/100
Event
Earnings
Published
13 Jul 2026 18:10
Source
Investing.com
Quiver Quantitative Direct company coverage

Artelo Biosciences Announces ART27.13 Data Suggest Potential Benefit for Neuropathic Pain in Cancer Patients

Artelo Biosciences announced promising nonclinical and interim clinical data for ART27.13, their proprietary cannabinoid receptor agonist, suggesting its potential to treat neuropathic pain and cancer-related anorexia cachexia syndrome (CACS) in cancer patients. Nonclinical studi

Tone
Positive 73/100
Event
Market update
Published
13 Jul 2026 13:10
Source
Quiver Quantitative
Stock Titan Direct company coverage

Cancer pain study: ART27.13 eases nerve pain signs in paclitaxel-treated animals

Artelo Biosciences announced positive nonclinical data for its drug ART27.13, showing it reduced neuropathic pain in animals treated with paclitaxel. These findings suggest a broader application for ART27.13 in cancer supportive care beyond its current Phase 2 development for can

Tone
Positive 75/100
Event
Market update
Published
13 Jul 2026 13:01
Source
Stock Titan
Market source Direct company coverage

Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy

Artelo Biosciences announced positive results for ART27.13 in a nonclinical model of paclitaxel-induced peripheral neuropathy, a common and debilitating side effect of chemotherapy. The study showed that ART27.13 reduced neuropathic pain behaviors in animals, suggesting its poten

Tone
Positive 81/100
Event
Earnings
Published
13 Jul 2026 09:02
Source
Market source
Finviz Direct company coverage

ARTL - Artelo Biosciences Inc Latest SEC Filings

This article provides the latest SEC filings and comprehensive financial data for Artelo Biosciences Inc (ARTL). It includes key metrics such as market capitalization, income, sales, various financial ratios, insider ownership, institutional ownership, and stock performance data.

Tone
Negative 33/100
Event
Market update
Published
02 Jul 2026 12:11
Source
Finviz
Moomoo Direct company coverage

Artelo Biosciences Announces New Data Support

This article announces that Artelo Biosciences has revealed new data supporting its research. The company's findings are expected to have significant implications for its ongoing projects and future developments. Further details about the data and its impact may be available from

Tone
Positive 68/100
Event
Market update
Published
02 Jul 2026 10:40
Source
Moomoo
The Manila Times Direct company coverage

Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury

Artelo Biosciences announced new preclinical data supporting ART26.12 as a potential first-in-class therapy for chronic neuropathic pain associated with spinal cord injury. The study, conducted at Stony Brook University, showed that ART26.12, a selective FABP5 inhibitor, alleviat

Tone
Positive 71/100
Event
Market update
Published
01 Jul 2026 22:39
Source
The Manila Times
Stock Titan Direct company coverage

Artelo's ART26.12 eased spinal cord injury pain in mice

Artelo Biosciences announced new preclinical data supporting ART26.12 as a potential "first-in-class" therapy for chronic pain associated with spinal cord injury. Studies in mice demonstrated that ART26.12, a selective FABP5 inhibitor, reduced mechanical hypersensitivity, decreas

Tone
Positive 72/100
Event
Market update
Published
01 Jul 2026 13:09
Source
Stock Titan
Investing.com Direct company coverage

Artelo presents research on FABP5 inhibitor ART26.12

Artelo Biosciences presented research findings on its lead drug candidate ART26.12, a FABP5 inhibitor, at an international symposium. The multi-omics analyses identified linoleic acid as a central link in FABP5 inhibition, aligning with previous cancer research. Despite a signifi

Tone
Positive 67/100
Event
Market update
Published
01 Jul 2026 08:40
Source
Investing.com